$APPY (Venaxis, Inc.)

$APPY {{ '2016-09-14T08:07:10+0000' | timeago}} • Announcement

$APPY said it has acquired Boulder, CO-based BiOptix Diagnostics. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance technology for detection of molecular interactions. $APPY acquired as of Sept. 12 about 98% of voting shares of BiOptix for about 14% of $APPY post-deal outstanding shares. Terms of acquisition were not disclosed.

$UNH {{ '2018-01-17T13:48:18+0000' | timeago}} • Announcement

Largest US health insurer UnitedHealth's profits more than doubled in the fourth quarter to $3.61Bil due to tax benefits. $UNH also crossed $200Bil mark in revenues for FY17. The company now expects to save $1.7Bil in FY18 due to tax reforms. For 2018, the health insurer expects GAAP EPS between $11.65-11.95 and non-GAAP EPS between $12.30-12.60.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$UNH {{ '2018-01-16T17:58:43+0000' | timeago}} • Infographic

$UNH UnitedHealth Group Incorporated Earnings AlphaGraphic: Q4 2017 Highlights

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$NEOG {{ '2018-01-03T15:11:55+0000' | timeago}} • Announcement

Revenue of $NEOG rose 12% to $101.8MM in 2Q18. In the quarter, net income soared 53% to $17.1MM or $0.33 per diluted share, adjusted for a 4-for-3 stock split.

$MYGN {{ '2018-01-03T13:32:07+0000' | timeago}} • Announcement

$MYGN said $AZN will use its myChoice HRD Plus test in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza & Avastin. Under the agreement, $MYGN will use its myChoice Plus test to evaluate patients enrolled in an ongoing Phase III trial. Financial terms were not disclosed.

$NEOG {{ '2018-01-02T14:44:27+0000' | timeago}} • Announcement

$NEOG announced that all shares of its common stock will begin trading on a post-split basis to reflect the company’s 4-for-3 stock split. The price of the common stock will be adjusted downward by 25% from $82.21 to approx. $61.66 to account for the split. The adjusted price will be in effect on Jan. 2, 2018.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$ANTM {{ '2017-12-11T14:59:25+0000' | timeago}} • Infographic

At a time when the US health insurance sector stares at a rise in premium prices, amid the government’s move to repeal the Individual Mandate clause, an analysis shows that major players in the sector registered consistent revenue growth over the past ten years. $ANTM $UNH $AET $HUM $CI

$CELG {{ '2017-12-11T14:27:28+0000' | timeago}} • Announcement

$CELG and $JUNO report additional data from the TRANSCEND study. Celgene added that the results of this study show the potential for the CAR T therapy, a therapy to treat cancers. Application filing is expected to be completed in 2H18, with approval as early as the end of 2018. In June 2015, Celgene partnered with Juno Therapeutics by paying $1Bil.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
NEOG (Neogen Corp.)
Wednesday, January 3 2018 - 4:00pm
IMMU (Immunomedics Inc.)
Thursday, November 9 2017 - 10:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
MYGN (Myriad Genetics, Inc.)
Tuesday, November 7 2017 - 9:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
QDEL (Quidel Corp.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
QTNT (Quotient Limited)
Tuesday, October 31 2017 - 12:30pm
OXFD (Oxford Immunotec Global PLC)
Tuesday, October 31 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
TRIB (Trinity Biotech plc)
Thursday, October 26 2017 - 3:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
NEOG (Neogen Corp.)
Tuesday, September 19 2017 - 3:00pm
IMMU (Immunomedics Inc.)
Wednesday, August 16 2017 - 9:00pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm

AlphaGraphics you may like